scholarly journals (Ferric carboxymaltose - a promising molecule in the treatment of iron deficiency in patients with heart failure)

Cor et Vasa ◽  
2021 ◽  
Vol 63 (6) ◽  
pp. 737-740
Author(s):  
Mária Bakošová ◽  
Jan Krejčí ◽  
Lenka Špinarová
Keyword(s):  
Heart Failure ◽  
Iron Deficiency ◽  
Ferric Carboxymaltose ◽  
Patients With Heart Failure

scholarly journals Expert consensus regarding treatment of iron deficiency in stable and decompensated patients with heart failure

Kardiologiia ◽  
2021 ◽  
Vol 61 (4) ◽  
pp. 73-78
Author(s):  
Yu. V. Mareev ◽  
S. R. Gilarevsky ◽  
Yu. L. Begrambekova ◽  
Yu. M. Lopatin ◽  
A. A. Garganeeva ◽  
...  
Keyword(s):  
Heart Failure ◽  
Iron Deficiency ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Ferric Carboxymaltose ◽  
Ventricular Ejection Fraction ◽  
Patients With Heart Failure ◽  
High Prevalence ◽  
Acute Decompensation

In recent years there has been significant interest in treating iron deficiency (ID) in patients with heart failure (HF) due to its high prevalence and detrimental effects in this population. As stated in the 2020 Russain HF guidelines, Intravenous ferric carboxymaltose remains the only proven therapy for ID.This document was prompted by the results from the recent AFFIRM-AHF trial which demonstrates that treatment of ID after acute HF decompensation reduces the risk of future decompensations. Experts have concluded that in HF patients with acute decompensation, a left ventricular ejection fraction of < 50% and ID, Intravenous ferric carboxymaltose reduces future HF hospitalisations. Patients with stable HF may also benefit from treatment of ID to improve quality of life and alleviate symptoms.  It is, therefore, reasonable to screen for and treat ID in patients with HF.

scholarly journals Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency

2009 ◽  
Vol 361 (25) ◽  
pp. 2436-2448 ◽  
Author(s):  
Stefan D. Anker ◽  
Josep Comin Colet ◽  
Gerasimos Filippatos ◽  
Ronnie Willenheimer ◽  
Kenneth Dickstein ◽  
...  
Keyword(s):  
Heart Failure ◽  
Iron Deficiency ◽  
Ferric Carboxymaltose ◽  
Patients With Heart Failure

scholarly journals Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis

2013 ◽  
Vol 168 (4) ◽  
pp. 3878-3883 ◽  
Author(s):  
Florian S. Gutzwiller ◽  
Alena M. Pfeil ◽  
Josep Comin-Colet ◽  
Piotr Ponikowski ◽  
Gerasimos Filippatos ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Iron Deficiency ◽  
Ferric Carboxymaltose ◽  
Patients With Heart Failure
Sign in / Sign up

Export Citation Format

Share Document